US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

AgomAb Therapeutics / Equity Capital Markets

<ul>
<li>FDA alignment on its Phase 2b Crohn's disease study reignited investor interest, but shares remain below the IPO price despite a sharp June rally.</li>
<li>Volatile trading reflects biotech's data-driven nature, with AGMB swinging from a post-IPO low of $8.75 to nearly $18.00 on positive regulatory news.</li>
<li>Improving biotech IPO sentiment provides a more supportive backdrop, though meaningful upside will likely require successful clinical execution and additional data.</li>
</ul>


FDA alignment on its Phase 2b Crohn's disease study reignited investor interest, but shares remain below the IPO price despite a sharp June rally.
Volatile trading reflects biotech's data-driven nature, with AGMB swinging from a post-IPO low of $8.75 to nearly $18.00 on positive regulatory news.
Improving biotech IPO sentiment provides a more supportive backdrop, though meaningful upside will likely require successful clinical execution and additional data.


AgomAb Therapeutics NV (AGMB): Six Months Later: A Regulatory Win Sparks Life, IPO Story Unfinished

<ul>
<li>AgomAb Therapeutics priced at $16.00 but opened down 8.1%, reflecting weak aftermarket support despite reported oversubscription.</li>
<li>Shares traded volatile on day one, hitting $12.66 before rebounding to close at $14.65, still below the IPO price.</li>
<li>The deal highlights the fragility of biotech IPO demand, where a few institutional orders can materially sway outcomes.</li>
</ul>


AgomAb Therapeutics priced at $16.00 but opened down 8.1%, reflecting weak aftermarket support despite reported oversubscription.
Shares traded volatile on day one, hitting $12.66 before rebounding to close at $14.65, still below the IPO price.
The deal highlights the fragility of biotech IPO demand, where a few institutional orders can materially sway outcomes.


AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

<ul>
<li>Agomab Therapeutics (AGMB US) targets a February 6 IPO, backed by Pfizer with a valuation of up to $829m.</li>
<li>Lead asset ontunisertib addresses fibrostenosing Crohn’s disease, a large underserved market, supported by a differentiated, GI-restricted ALK5 inhibition strategy.</li>
<li>A blue-chip investor base and strong underwriting syndicate support an attractive near-term risk-reward profile, though institutional and sector-dedicated order flow remains a key variable.</li>
</ul>


Agomab Therapeutics (AGMB US) targets a February 6 IPO, backed by Pfizer with a valuation of up to $829m.
Lead asset ontunisertib addresses fibrostenosing Crohn’s disease, a large underserved market, supported by a differentiated, GI-restricted ALK5 inhibition strategy.
A blue-chip investor base and strong underwriting syndicate support an attractive near-term risk-reward profile, though institutional and sector-dedicated order flow remains a key variable.


AgomAb Therapeutics NV (AGMB): Belgium-Based Biotech Set to IPO with Strong Pharma Backing

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality &amp; Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under the ticker AGMB as a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibrotic and inflammatory conditions.</li><li>The IPO consists of approximately 12.5 million American Depositary Shares (ADS) priced between $15-$17 per ADS, with additional capacity through an underwriter overallotment.</li><li>At the midpoint, the offering raises just over $200 million and implies a valuation in the high hundreds of millions.</li></ul>

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality &amp; Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under the ticker AGMB as a clinical-stage biopharmaceutical company developing disease-modifying therapies for fibrotic and inflammatory conditions.The IPO consists of approximately 12.5 million American Depositary Shares (ADS) priced between $15-$17 per ADS, with additional capacity through an underwriter overallotment.At the midpoint, the offering raises just over $200 million and implies a valuation in the high hundreds of millions.

<ul><li>AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO activity selectively reopens in early 2026.</li><li>The company plans to offer 12.5 million ADSs at a proposed price range of $15.00 to $17.00 per share , raising approximately $200 million in gross proceeds at the $16.00 midpoint , before underwriting expenses.</li><li>At the midpoint, AgomAb would have an implied equity value of approximately $780 million , based on roughly 48.7 million shares outstanding following the offering.</li></ul>

AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO activity selectively reopens in early 2026.The company plans to offer 12.5 million ADSs at a proposed price range of $15.00 to $17.00 per share , raising approximately $200 million in gross proceeds at the $16.00 midpoint , before underwriting expenses.At the midpoint, AgomAb would have an implied equity value of approximately $780 million , based on roughly 48.7 million shares outstanding following the offering.

AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline

Belgium

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications. The company's pipeline includes small molecule and antibody product candidates, such as Ontunisertib (AGMB-129) for Crohn's disease and AGMB-447 for idiopathic pulmonary fibrosis. AgomAb Therapeutics was founded in 2017 and is headquartered in Antwerp, Belgium.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AgomAb Therapeutics (AGMB US)

AgomAb Therapeutics NV (AGMB): Six Months Later: A Regulatory Win Sparks Life, IPO Story Unfinished

FDA alignment on Phase 2b Crohn's study reignites investor interest in AGMB, despite shares remaining below IPO price. The stock closed Monday's...

IPO Boutique

AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

AgomAb Therapeutics IPO opens below price at $14.65, showing vulnerability of biotech IPO demand to institutional orders.

IPO Boutique

AgomAb Therapeutics NV (AGMB): Belgium-Based Biotech Set to IPO with Strong Pharma Backing

Agomab Therapeutics set for IPO with Pfizer backing, targeting fibrostenosing Crohn's disease market with promising asset ontunisertib.

IPO Boutique

IPO Rating: AgomAb Therapeutics NV

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality & Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under...

IPO Prophet

AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline

AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

AgomAb Therapeutics NV (AGMB): Six Months Later: A Regulatory Win Sparks Life, IPO Story Unfinished

​FDA alignment on Phase 2b Crohn's study reignites investor interest in AGMB, despite shares remaining below IPO price. The stock closed Monday's...

IPO Boutique

AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

​AgomAb Therapeutics IPO opens below price at $14.65, showing vulnerability of biotech IPO demand to institutional orders.

IPO Boutique

AgomAb Therapeutics NV (AGMB): Belgium-Based Biotech Set to IPO with Strong Pharma Backing

​Agomab Therapeutics set for IPO with Pfizer backing, targeting fibrostenosing Crohn's disease market with promising asset ontunisertib.

IPO Boutique

IPO Rating: AgomAb Therapeutics NV

✅ IPO PROPHET RATING: 7.7/10 🏦 Deal Quality & Underwriters: 8.1/10 AgomAb Therapeutics is preparing to list on the Nasdaq Global Market under...

IPO Prophet

AgomAb Therapeutics Sets Terms for IPO as Fibrosis-Focused Biotech Advances Clinical Pipeline

AgomAb Therapeutics NV has set terms for its initial public offering, positioning the fibrosis-focused biotech to access the public markets as IPO...

IPO Prophet

FDA alignment on Phase 2b Crohn's study reignites investor interest in AGMB, despite shares remaining below IPO price. The stock closed Monday's...

AgomAb Therapeutics IPO opens below price at $14.65, showing vulnerability of biotech IPO demand to institutional orders.

Agomab Therapeutics set for IPO with Pfizer backing, targeting fibrostenosing Crohn's disease market with promising asset ontunisertib.